Moreover, SHP2 inhibition has recently been shown to reduce MAPK and mTOR signaling via inactivation of ERK, mTORC1, and S6K in neuroblastoma cells and tumors with low NF1 expression (41). The gene discussed is MAPK1; the disease is neuroblastoma.